The Center for Advanced Preclinical Research partners with the National Cancer Institute and extramural investigators to develop novel strategies for preclinical evaluation of experimental therapeutics using distinct mouse models of cancer. Our collaborative approach allows us to carry out optimized, reproducible preclinical studies aimed at developing effective treatments for human cancers. 

Optimized preclinical studies guide clinical research for better cancer patient outcomes 

Preclinical studies are critical for understanding whether a cancer treatment might work in humans. We are distinctly, if not uniquely, positioned to assess novel therapies and treatment delivery methods using mouse cancer models that closely mimic human cancer biologies. The goal is to identify promising treatments and weed out those that are likely to fail, thus increasing the chances that potential cures can move into the clinic.  

Additional Content

Integration of laboratory and animal model research 

Mammary gland of mouse model of breast cancer showing early signs of carcinoma
Mammary gland of mouse model of breast cancer showing early signs of carcinoma. 

Our team offers an integrated workflow for in vivo studies, from evaluating therapeutic agents in tumor cells to planning and executing in vivo antitumor efficacy and cancer prevention studies. We offer validated, genetically engineered or patient-derived tumor mouse models for numerous cancer types.

Additional Content

Investigating therapies in multiple cancer models 

We are evaluating treatments for melanoma and glioblastoma, as well as breast, ovarian, lung, pancreatic, and blood cancers, using diverse approaches in our predictive mouse cancer models. We are currently collaborating with intramural NCI investigators and the Division of Cancer Prevention.

Our capabilities and specializations

Additional Content

Treatments and therapies in mice

We test cutting-edge treatments, such as antibody and cell-based therapies, in mice with functioning immune systems. These assessments are less informative when performed in the immunocompromised mice often used in cancer studies.

Additional Content
  • Checkpoint inhibitors 

  • Antibody–drug conjugates 

  • Immunotoxins 

  • CAR T-cell therapy 

Additional Content

Evaluating therapeutic efficacy in preclinical cancer models

We use optimized methods, technologies, and processes to improve throughput and scale-up of preclinical studies.

Additional Content
  • Imaging 

  • Tumor analysis 

  • Toxicology assessments